ALK and non-small cell lung carcinoma: The first MET inhibitor to obtain FDA approval was the multi-kinase inhibitor crizotinib (Xalkori, Pfizer, New York, NY, USA), which was approved for the treatment of patients with ALK-rearranged NSCLC more than 10 years ago [18].